Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease

Kidney International

Volumn 79, Issue 1, 2011, Pages 128-134

  Reed, Berenice Y ^a   Masoumi, Amirali ^a   Elhassan, Elwaleed ^a   McFann, Kim ^a,b   Cadnapaphornchai, Melissa A ^c,d   Maahs, David M ^c,e   Snell Bergeon, Janet K ^c,e   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Global Health and Health Disparities   (United States)

^c Children's Hospital Colorado   (United States)

^d CHILDREN S HOSPITAL COLORADO   (United States)

^e UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

ADPKD; cardiovascular disease; children; kidney volume; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; GROWTH FACTOR; VASCULOTROPIN;

ADULT; AGE DISTRIBUTION; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR PARAMETERS; CHILD; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY STRUCTURE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SCHOOL CHILD; URINARY EXCRETION;

EID: 78650282469     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.355     Document Type: Article

References (36)

1. Ecder T, Fick-Brosnahan G, Schrier RW. Polycystic kidney disease, in Diseases of the Kidney and Urinary Tract (vol 1), ed. Schrier RW. Lipincott, Williams and Wilkins: Philadelphia, 2007, pp 502-539.
2. Chapman AB, Guay-Woodford LM, Grantham JJ et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003; 64: 1035-1045.
3. Seeman T, Dusek J, Vondrichova H et al. Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 2003; 8: 107-110.
4. Fick-Brosnahan GM, Tran ZV, Johnson AM et al. Progression of autosomal dominant polycystic kidney disease in children. Kidney Int 2001; 5: 1654-1662.
5. Cadnapaphornchai MA, McFann K, Strain JD et al. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 2008; 74: 1192-1196.
6. Cadnapaphornchai M, McFann K, Strain JD et al. Prospective changes in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 2009; 4: 820-829.
7. Bello-Reuss E, Holubec K, Rajaraman S et al. Angiogenesis in autosomal dominant polycystic kidney disease. Kidney Int 2001; 60: 37-45.
8. Wei W, Popov V, Walocha JA et al. Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study. Kidney Int 2006; 70: 1261-1268.
9. Nichols MT, Gidney E, Matzakos T et al. Secretion of cytokines and growth factors into ADPKD liver cyst fluid. Hepatology 2004; 40: 836-846.
10. Fabris L, Cadamuro M, Fiorotto R et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver disease. Hepatology 2004; 43: 1001-1012.
11. Otrock ZK, Mahfouz RAR, Makarem JA et al. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007; 39: 211-220.
12. Augustin HG, Koh GY, Thurston G et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-177.
13. Suri C, McClain J, Thurston G et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-471.
14. Lovegrove FE, Tangpukdee N, Opoka RO et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PlosOne 2009; 4: e4912, 2009.
15. Fielder U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-558.
16. Bolin M, Wiberg-Itzel E, Wilkstrom AK et al. Angiopoietin-1/angiopoietin- 2 ratio for prediction of preeclampsia. Am J Hypertens 2009; 22: 891-895.
17. Lim HS, Lip GYH, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005; 180: 113-118.
18. Sascha D, Kumpers P, Hellpap J et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kid Dis 2009; 53: 770-778.
19. Nadar SK, Blann AD, Lip GYH. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Int Med 2004; 256: 331-337.
20. Nadar SK, Blann A, Beevers DG et al. Abnormal angiopoietins 1 & 2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandanavian Cardiac Outcomes Trial (ASCOT)]. J Int Med 2004; 258: 336-343.
21. Kramer CY. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 1966; 12: 307-310.
22. Amura CA, Brodsky KS, Groff R et al. VEGF receptor inhibition blocks liver cyst growth in pkd(WS25/-)mice. Am J Cell Physiol 2007; 293: C419-C428.
23. Heshmat NM, El-Kerdany TH. Serum levels of vascular endothelial growth factor in children and adolescents with sytemic lupus erythematosus. Pediatr Allergy Immunol 2007; 18: 346-353.
24. Mysliwiec M, Balcerska A, Zorena K et al. The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Care Clin Practice 2008; 79: 141-146.
25. Yang YB, Liu F, Huang SM. The expression and significance of the angiopoietin-1 in the kidney of diabetic rats. Sichuan Da Xue Xue Bao Yi Xue Ban 2007; 38: 93-96.
26. Chapman AB, Johnson AM, Rainguet S et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997; 8: 1292-1297.
27. Park YS, Kim NH, Jo I. Hypoxia and vascular endothelial growth factor acutely up-regulate angiopoietin-1 and Tie2 mRNA in bovine retinal pericytes. Microvasc Res 2003; 65: 125-131.
28. Singh H, Milner CS, Aguilar Hernandez MM et al. Vascular endothelial growth factor activates the tie family of receptor tyrosine kinases. Cell Signal 2009; 21: 1346-1350.
29. Chapman AB, Johnson AM, Gabow P et al. The renin-angiotensin-aldosterone system and autosomal polycystic kidney disease. N Eng J Med 1990; 323: 1091-1096. (Pubitemid 20370729)
30. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2009; 20: 1888-1893.
31. Barrett BJ, Foley R, Morgan J et al. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994; 46: 1118-1123.
32. Harrap SB, Davies DL, Macnicol AM et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991; 40: 501-508.
33. Rizkalla B, Forbes JM, Cooper ME et al. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003; 14: 3061-3071.
34. Kitayama H, Maeshima Y, Takazawa Y et al. Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 2006; 19: 718-727.
35. Herr D, Rodewald M, Fraser HM et al. Regulation of endothelial proliferation by the renin-angiotensin system in human umbilical vein endothelial cells. Reproduction 2008; 136: 125-130.
36. Ravine D, Gibson RN, Walker RG et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney 1. Lancet 1994; 343: 824-827.